Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin

New England Journal of Medicine

Volumn 340, Issue 16, 1999, Pages 1228-1233

  Kenny Walsh, Elizabeth ^a   Shanahan, Fergus ^a  

^a Cork University Hospital ^*  (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RHESUS D ANTIBODY;

ADULT; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHESUS ISOIMMUNIZATION; SCREENING TEST; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; BIOPSY; DISEASE OUTBREAKS; DISEASE PROGRESSION; DRUG CONTAMINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IRELAND; LIVER; LIVER CIRRHOSIS; MASS SCREENING; MIDDLE AGED; RHO(D) IMMUNE GLOBULIN; RISK FACTORS; RNA, VIRAL;

EID: 0033594380     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199904223401602     Document Type: Article

References (40)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
2. McOmish F, Chan S-W, Dow BC, et al. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993;33:7-13.
3. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
4. Muller R. The natural history of hepatitis C: clinical experiences. J Hepatol 1996;24:Suppl:52-4.
5. Schiff RI. Transmission of viral infections through intravenous immune globulin. N Engl J Med 1994;331:1649-50.
6. Bjøro K, Frøland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331: 1607-11.
7. Alter MJ. Transmission of hepatitis C virus - route, dose, and titer. N Engl J Med 1994;330:784-6.
8. Gordon SC, Elloway RS, Long JC, Dmuchowski CF The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. Hepatology 1993;18:1338-43.
9. Donahue JG, Muñoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
10. Alter HJ, Seeff LB. Transfusion-associated hepatitis. In: Zucherman AJ, Thomas HC, eds. Viral hepatitis. Edinburgh, Scotland: Churchill Livingstone, 1993:467-99.
11. Dodd RY. The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419-21.
12. The Japanese Red Cross Non-A, Non-B Hepatitis Research Group. Effect of screening for hepatitis C virus antibody and hepatitis B virus core antibody on incidence of post-transfusion hepatitis. Lancet 1991;338: 1040-1.
13. Dittmann S, Roggendorf M, Durkop J, Wiese M, Lorbeer B, Deinhardt F. Preliminary results of a long term follow-up of antibody response to hepatitis C virus infections after administration of contaminated immunoglobulin. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:422-3.
14. Power JP, Lawlor E, Davidson F, Holmes EC, Yap PL, Simmonds P. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 1995;345:1211-3.
15. Power JP, Lawlor E, Davidson F, et al. Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 1994;344:1166-7.
16. Report of the Expert Group on the Blood Transfusion Service Board. Dublin, Ireland: Stationery Office, 1995.
17. Finlay TA. Report of the Tribunal of Inquiry into the Blood Transfusion Service Board. Dublin, Ireland: Stationery Office, 1997:176-83.
18. Hepatitis C Compensation Tribunal Act 1997. Dublin, Ireland: Stationery Office, 1997.
19. Central Statistics Office. Annual vital statistics. Dublin, Ireland: Stationery Office, 1977-1992.
20. Crowe J, Doyle C, Fielding JF, et al. Presentation of hepatitis C in a unique uniform cohort 17 years from inoculation. Gastroenterology 1995; 108:Suppl:A1054. abstract.
21. Sheehan MM, Doyle CT, Whelton M, Kenny-Walsh E. Hepatitis C virus liver disease in women infected with contaminated anti-D immunoglobulin. Histopathology 1997;30:512-7.
22. Paton A, Saunders JB. ABC of alcohol: definitions. BMJ 1981;283: 1248-50.
23. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
24. Terminology of chronic hepatitis, hepatic allograft rejection and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994. Am J Gastroenterol 1994;89:Suppl: S177-S181.
25. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
26. Simmonds P. Typing of HCV: a comparison of PCR-based and serological methods. Mol Diagn 1993;1(5):4-5.
27. Brechot CB. The current status and future promise for the use of PCR in hepatitis C virus infection diagnosis. Mol Diagn 1993;1(5):2-3.
28. Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford, England: Blackwell Scientific, 1994.
29. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994;32:884-92.
30. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62. [Erratum, N Engl J Med 1996;334:1143.]
31. Dienstag JL. The natural history of chronic hepatitis C and what we should do about it. Gastroenterology 1997;112:651-5.
32. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
33. Tremolada F, Casarin C, Alberti A, et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-81.
34. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-4. [Erratum, Lancet 1993;342:504.]
35. Zeuzem S, Teuber G, Lee J-H, Ruster B, Roth WK. Risk factors for the transmission of hepatitis C, J Hepatol 1996;24:Suppl:3-10.
36. Seeff LB, Busked-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327: 1906-11.
37. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-6.
38. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
39. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
40. Yamakawa Y, Sata M, Suzuki H, Noguchi S, Tanikawa K. Higher elimination rate of hepatitis C virus among women. J Viral Hepat 1996;3:317-21.